A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China

Sponsor
Bristol-Myers Squibb
Study ID
NCT07361289
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to assess the effectiveness of mavacamten treatment in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in real-world clinical practice

Key Dates

Start date
Jan 15, 2026
Status verified
May 2026
Primary completion
Aug 22, 2028
Completion
Aug 28, 2028

Study Design

Enrollment
500 participants (estimated)

Arms

  • Arm: Cohort 1
    Participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) receiving mavacamten

Primary Outcome Measure

Change from baseline in Valsalva left ventricular outflow tract (LVOT) gradient [ Time Frame: Week 48, Week 96 ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Related Studies